Biography
RuiHui (Rachel) Yu is a partner in Sullivan & Cromwell LLP’s New York office and a member of the Firm’s General Practice Group. Rachel’s practice concentrates on transactional work involving complex technology, intellectual property, and cybersecurity issues, including mergers and acquisitions, divestitures, licenses and transfers of intellectual property, joint ventures, research and development agreements, collaborations, and strategic advice.
Rachel counsels clients across the industry spectrum, including within the healthcare and life sciences industry. She has recently advised Seagen in its $43 billion acquisition by Pfizer, Abiomed in its $18 billion acquisition by Johnson & Johnson, Amgen in its $27.8 billion acquisition of Horizon Therapeutics, and Biohaven in several commercial arrangements and its $11.6 billion sale to Pfizer. Additional clients in this space include Anika Therapeutics, Bausch Health, Bayer, Novartis, Sumitomo Pharma, UnitedHealth Group and Verily Life Sciences.
Rachel is a thought-leader in the field, regularly speaking on topics involving artificial intelligence and other intellectual property issues, and serves as a Lecturer in Law at Columbia Law School. Rachel is also committed to pro bono work, having co-led the Legal Aid Society’s Associates’ Campaign in its annual fundraising efforts, and having represented clients in transgender name changes and through the Clemency Project.
Rachel holds a J.D. from Stanford Law School, where she received the President’s Award as an editor of the Stanford Law Review. She earned her A.B. from Princeton University and her M.S. from Stanford University.
